RadNet (RDNT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.29
- Estimate
- $0.20
- Surprise
- +44.0%
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
RadNet (RDNT) beat the $0.20 estimate with adjusted EPS of $0.29 — a large 44.0% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates RDNT Sell at 5.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +44.0% surprise compares with a -0.3% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (2.6 < 4.0)
- Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow
- Reward/Risk 1.0:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $74.12
- Price target
- $82.32
- Stop
- $69.82
- Upside to target
- +11.1%
- Reward-to-risk
- 1.0:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
RDNT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $5.79B
- P/E (fwd)
- 89.7
- 52-week range
- $50.82–$85.84
- Off 52-week high
- 13.7%
- RSI (14)
- 61
- Volume vs avg
- 0.19×
- Score today
- 5.6/10